Drug Reaction with Eosinophilia and Systemic Symptoms

Comprehensive Clinical Guide: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

DRESS syndrome, also known as Drug-Induced Hypersensitivity Syndrome (DiHS), represents a severe, potentially life-threatening idiosyncratic drug reaction. It is classified as a Delayed-Type Hypersensitivity (DTH) reaction that affects not only the skin but also internal organs, distinguishing it from milder cutaneous drug eruptions.

1. Introduction and Overview

DRESS syndrome is characterized by a long latency period between drug initiation and symptom onset, typically ranging from two to eight weeks. Unlike simple maculopapular rashes, DRESS involves systemic involvement, hematologic abnormalities, and significant morbidity. The mortality rate is estimated between 5% and 10%, necessitating prompt recognition, immediate discontinuation of the offending agent, and aggressive supportive care.

The diagnostic landscape of DRESS is defined by the RegiSCAR criteria, which categorize patients based on clinical and laboratory findings. The syndrome is a multisystem entity, often involving the liver, kidneys, lungs, and heart.

2. Etiology and Pathophysiology

The pathophysiology of DRESS is multifactorial, involving a complex interplay between drug metabolism, immune system activation, and viral reactivation.

The Triad of Pathogenesis

1. Drug Metabolism Defects: Genetic polymorphisms in enzymes (e.g., Cytochrome P450) lead to the accumulation of reactive drug metabolites, which act as haptens.
2. Immune Dysregulation: The drug-hapten complex binds to T-cell receptors, triggering a massive expansion of drug-specific CD4+ and CD8+ T-cells.
3. Viral Reactivation: DRESS is uniquely associated with the reactivation of human herpesviruses, specifically HHV-6, HHV-7, EBV, and CMV. This viral "flare" exacerbates the systemic inflammatory response.

Common Offending Agents

3. Clinical Presentation and Staging

Standard Clinical Presentation

• Cutaneous: A morbilliform rash that often starts on the face or upper trunk and spreads symmetrically. Facial edema is a hallmark sign.
• Systemic: High-grade fever (often >38.5°C), generalized lymphadenopathy, and malaise.
• Organ Involvement:
  • Liver: Hepatitis (elevated transaminases).
  • Kidneys: Interstitial nephritis.
  • Lungs: Pneumonitis or pleural effusion.
  • Hematologic: Eosinophilia (the defining feature), atypical lymphocytosis.

Clinical Grading (RegiSCAR Criteria)

To confirm the diagnosis, clinicians utilize the RegiSCAR scoring system:
* Definite Case: Score > 5
* Probable Case: Score 4-5
* Possible Case: Score 2-3
* No Case: Score < 2

4. Differential Diagnosis

DRESS must be differentiated from other severe cutaneous adverse reactions (SCARs):

1. Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN): Characterized by rapid epidermal detachment and mucosal involvement, which are generally absent in DRESS.
2. Acute Generalized Exanthematous Pustulosis (AGEP): Presents with sterile pustules and a much shorter latency period (days, not weeks).
3. Viral Exanthems: Measles, rubella, or infectious mononucleosis can mimic the rash but lack the internal organ systemic severity of DRESS.
4. Autoimmune Diseases: Systemic Lupus Erythematosus (SLE) or Still’s disease may overlap in presentation but follow a different clinical trajectory.

5. Diagnostic Testing and Evaluation

A standardized diagnostic workup is essential for managing DRESS:

• Complete Blood Count (CBC): Monitor for eosinophilia and atypical lymphocytes.
• Comprehensive Metabolic Panel (CMP): Assess hepatic (ALT/AST, bilirubin) and renal (BUN/Creatinine) function.
• Viral Serology: PCR testing for HHV-6, EBV, and CMV to assess for reactivation.
• Skin Biopsy: Usually reveals perivascular lymphocytic infiltrates with eosinophils.
• Imaging: Chest X-ray or CT to evaluate for pneumonitis or lymphadenopathy.

6. Risks, Contraindications, and Management

Immediate Management

1. Stop the offending drug: This is the most critical intervention.
2. Supportive Care: Fluid resuscitation, electrolyte management, and topical corticosteroids for skin symptoms.
3. Systemic Steroids: High-dose systemic corticosteroids (prednisone 0.5–1.0 mg/kg/day) are the standard of care for patients with significant organ involvement.
4. Tapering: Steroids must be tapered slowly over 6–8 weeks; rapid withdrawal often leads to a rebound of symptoms.

Contraindications

• Re-challenge: Never re-challenge the patient with the suspected drug.
• Avoid unnecessary medications: The immune system is hyper-reactive; unnecessary polypharmacy can trigger a secondary reaction.

7. Long-term Prognosis

While the acute phase is dangerous, long-term sequelae are emerging concerns. Research indicates that patients who recover from DRESS may be at higher risk for developing autoimmune diseases later in life, including:
* Type 1 Diabetes Mellitus
* Graves’ Disease
* Systemic Lupus Erythematosus (SLE)

Regular monitoring of thyroid function and autoimmune markers is recommended for 6–12 months post-recovery.

8. Massive FAQ Section

Q1: How long after taking a drug can DRESS occur?
A: Unlike typical allergic reactions, DRESS has a long latency period, usually 2 to 8 weeks after the initial exposure to the drug.

Q2: Is DRESS contagious?
A: No, DRESS is an idiosyncratic drug reaction. It is not an infectious disease, although viral reactivation is a component of the pathophysiology.

Q3: Can I ever take the medication that caused my DRESS again?
A: Absolutely not. Re-exposure to the offending drug can cause a rapid, potentially fatal recurrence of the syndrome.

Q4: Is facial edema a common sign?
A: Yes, facial edema is one of the most specific clinical indicators of DRESS and is often present in early stages.

Q5: Why do doctors test for HHV-6 in DRESS patients?
A: Reactivation of human herpesvirus 6 (HHV-6) is frequently observed in DRESS patients and is believed to contribute to the severity and duration of the systemic inflammatory response.

Q6: What is the primary cause of death in DRESS?
A: The most common causes of mortality are fulminant hepatitis and multi-organ failure.

Q7: Can children get DRESS?
A: Yes, although it is more common in adults, children can develop DRESS, often in response to anticonvulsants or antibiotics.

Q8: How long does the treatment last?
A: Treatment typically requires a long-term steroid taper, often lasting 6 to 8 weeks, to prevent disease relapse.

Q9: Does DRESS always involve the skin?
A: While skin involvement is a major diagnostic criterion, in extremely rare cases, the systemic manifestations can manifest before or without a prominent rash.

Q10: Are there genetic tests to predict DRESS?
A: There are specific HLA-allele associations (e.g., HLA-B*58:01 for allopurinol-induced DRESS) that allow for pre-screening in high-risk populations, but general screening for all drugs is not yet standard.

9. Conclusion

DRESS is a complex, systemic medical emergency that requires a high index of suspicion. As healthcare providers, recognizing the constellation of fever, rash, and hematologic abnormalities is the first line of defense. Through early identification, cessation of the causative agent, and carefully managed steroid therapy, the prognosis for the majority of patients remains favorable. Ongoing research into the genetic predisposition and the role of viral reactivation continues to refine our approach to this challenging clinical entity.